- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This is the first round of the IBBS survey conducted among Women Injecting Drug Users (WIDUs) in Pokhara Valley. The females of 16 years and above who had been injecting drugs for at least three months preceding the survey were defined as WIDUs and enrolled in the survey. School of Planning Monitoring Evaluation and Research (SPMER) carried out this survey from December 2016 to May 2017. The survey was undertaken primarily to determine the prevalence of HIV, syphilis, Hepatitis B (HBV) and Hepatitis C (HCV) infection among WIDUs. Moreover, the survey also find out the baseline data of comprehensive knowledge of HIV/AIDS, sexual risk behavior and injecting behaviors among WIDUs, their exposures to various HIV/AIDS prevention, treatment, care and support programs.
In the Middle East and North Africa (MENA) region, the access to Harm Reduction (HR), Human Immunodeficiency Virus (HIV) treatment, care and support services remains limited among People Living with HIV/AIDS-(PLHIV)-People Who Use Drugs (PWUDs)/People Who Inject Drugs (PWIDs). To acquire a comprehensive understanding of the drug use and HR situation among PLHIV-WUDs/WIDs, a Multicentre Operational Research (OR) was conducted by the Middle East and North Africa Harm Reduction Association (MENAHRA) with support from the Global Fund.
The report prepared by UNAIDS Regional Support Team for Asia and the Pacific and AIDS Data Hub provides information on the HIV epidemic and response on people who inject drugs in Asia and the Pacific.
Keywords: HIV, PWID, hepatitis C, drugs, needle and syringe
People who use drugs are heavily affected by HIV, hepatitis C (HCV), and tuberculosis (TB) and are often neglected in countries’ and cities’ responses to the epidemics. There are effective means to prevent and treat HIV, HCV and TB among people who use drugs, but resources (financial, human and material) are often not adequately invested to make them accessible. The reasons for this are multifaceted and include criminalization, stigma, discrimination and denial of basic human rights to people who use drugs. This IDUIT Brief Guide for People who Use Drugs is intended to outline the key concepts of Implementing Comprehensive HIV and HCV Programs with People who Inject Drugs: Practical Guidance for Collaborative Interventions (the IDUIT) related to prevention, treatment and empowerment with regard to HIV and HCV, and point to how activists and professionals from among the community of people who use drugs might promote better policy and practice.
Keywords: HIV/AIDS, human rights, hepatitis, community strengthening
To celebrate 20 years since its inception, the World Drug Report 2017 is presented in a new five-booklet format designed to improve reader friendliness while maintaining the wealth of information contained within.
Booklet 1 summarizes the content of the four subsequent substantive booklets and presents policy implications drawn from their findings. Booklet 2 deals with the supply, use and health consequences of drugs. Booklet 3 focuses on the cultivation, production and consumption of the three plant-based drugs (cocaine, opiates and cannabis) and on the impact of new cannabis policies. Booklet 4 provides an extended analysis of the global synthetic drugs market and contains the bulk of the analysis for the triennial global synthetic drugs assessment. Finally, Booklet 5 contains a discussion on the nexus between the drug problem, organized crime, illicit financial flows, corruption and terrorism.
This 2015, the Epidemiology Bureau of the Department of Health (DOH-EB), together with various partners conducted several activities with the goal of updating the size estimates of KAP in the country, specifically among Males who have Sex with Males (MSM), Female Sex Workers (FSW) and Injecting Drug Users (IDU).
Keywords: HIV, IHBSS sites, national level, mapping, city
In this report, the International Drug Policy Consortium (IDPC) offers recommendations based on evidence and examples of good practice to inform a shift in policy responses to drug use in Asia away from criminalisation and punishment, and towards public health and harm reduction. It describes effective approaches to the decriminalisation of drug use. It also discusses approaches implemented in Asia that have proven ineffective, such as the detention of people who use drugs in compulsory centres as a form of ‘rehabilitation’.
Evidence supports the need for a shift in the global approach to drug use. In this report, Do no harm: health, human rights and people who use drugs, UNAIDS shows what works to reduce the impact of HIV and other harms related to drug use. Countries that have moved away from laws and policies that are harmful to people who use drugs and that have increased investment in harm reduction have reduced new HIV infections and improved health outcomes. These policies also deliver broader social benefits, such as lower levels of drug-related crime and reduced pressure on health-care and criminal justice systems.
In Hong Kong, the number of HIV cases transmitted through injecting drug use (IDU) has remained low up till now and contributed to less than 5% of all reported cases cumulatively. However, the potential risk of cluster outbreak and rapid upsurge of infection among the IDU population is always a concern. To monitor HIV-related risk behaviours and access to HIV testing services among IDU, this population has been included as one of the four at-risk populations in the HIV/AIDS Response Indicator Survey (HARiS) implemented since 2013. The third round of survey was conducted in 2015 via commissioning to the Stanley Ho Centre for Emerging Infectious Disease, School of Public Health and Primary Care of the Chinese University of Hong Kong.
Keywords: Hong Kong, HIV, IDU, STI, sexual behaviours, testing, needle, condom
The period covered by this progress report has been highly eventful, not least because of the recent UN General Assembly Special Session on Drugs (UNGASS) which was held in April 2016. It is also the year in which IDPC proudly commemorates our 10th anniversary. IDPC was officially founded in 2006 after a small group of civil society organisations identified a need for a global network to coordinate advocacy efforts for drug policy reform. Since then the IDPC membership has grown exponentially in size, diversity of issues, visibility, and influence. We welcomed our 150th member this past year and we are as committed as ever to collective and collaborative advocacy to advance genuine and lasting reform in drug policies. In early 2016, we also finalised our strategy for the coming five years (2016 to 2020) which builds on our work to date and commits us to redouble our efforts in regional and national level networking while ensuring a strong link to the global debates.
Keywords: drugs, harm reduction, UNGASS, civil society